These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36878601)

  • 1. Impact of Tafamidis on Echocardiographic Cardiac Function of Patients With Transthyretin Cardiac Amyloidosis.
    Ichikawa Y; Oota E; Odajima S; Kintsu M; Todo S; Takeuchi K; Yamauchi Y; Shiraki H; Yamashita K; Fukuda T; Hisamatsu E; Hirata KI; Tanaka H
    Circ J; 2023 Mar; 87(4):508-516. PubMed ID: 36878601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy.
    Rettl R; Wollenweber T; Duca F; Binder C; Cherouny B; Dachs TM; Camuz Ligios L; Schrutka L; Dalos D; Beitzke D; Loewe C; Badr Eslam R; Kastner J; Hacker M; Bonderman D
    Eur Heart J Cardiovasc Imaging; 2023 Jul; 24(8):1019-1030. PubMed ID: 36881774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial.
    Shah SJ; Fine N; Garcia-Pavia P; Klein AL; Fernandes F; Weissman NJ; Maurer MS; Boman K; Gundapaneni B; Sultan MB; Elliott P
    JAMA Cardiol; 2024 Jan; 9(1):25-34. PubMed ID: 37966817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tafamidis on left atrial function of patients with transthyretin amyloid cardiomyopathy.
    Uemura K; Ichikawa Y; Nagai S; Nishihara Y; Todo S; Oota E; Odajima S; Takeuchi K; Kintsu M; Fukuda T; Hisamatsu E; Hirata KI; Tanaka H
    Heart Vessels; 2024 Sep; 39(9):810-817. PubMed ID: 38743105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy.
    Rettl R; Duca F; Binder C; Dachs TM; Cherouny B; Camuz Ligios L; Mann C; Schrutka L; Dalos D; Charwat-Resl S; Badr Eslam R; Kastner J; Bonderman D
    Amyloid; 2023 Mar; 30(1):127-137. PubMed ID: 36251806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report.
    Fujita T; Inomata T; Kaida T; Iida Y; Ikeda Y; Nabeta T; Ishii S; Maekawa E; Naruke T; Koitabashi T; Kitamura E; Sekijima Y; Ako J
    Cardiology; 2017; 137(2):74-77. PubMed ID: 28152524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies.
    Rozenbaum MH; Garcia A; Grima D; Tran D; Bhambri R; Stewart M; Li B; Heeg B; Postma M; Masri A
    Eur Heart J Qual Care Clin Outcomes; 2022 Aug; 8(5):529-538. PubMed ID: 33895806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of systematic screening and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with heart failure with preserved ejection fraction (HFpEF) in United States.
    Lau ATC; DiDomenico RJ; Kim K
    Int J Cardiol; 2024 Mar; 398():131598. PubMed ID: 37979789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.
    Park J; Egolum U; Parker S; Andrews E; Ombengi D; Ling H
    Ann Pharmacother; 2020 May; 54(5):470-477. PubMed ID: 31735059
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
    Elliott P; Drachman BM; Gottlieb SS; Hoffman JE; Hummel SL; Lenihan DJ; Ebede B; Gundapaneni B; Li B; Sultan MB; Shah SJ
    Circ Heart Fail; 2022 Jan; 15(1):e008193. PubMed ID: 34923848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Right Ventricular Strain Improves the Echocardiographic Diagnosis and Risk Stratification of Transthyretin Cardiac Amyloidosis Among Other Phenotypes of Left Ventricular Hypertrophy.
    Ozbay B; Satyavolu BS; Rearick C; Soman P; Katz WE; Sezer A; Sade LE
    J Am Soc Echocardiogr; 2024 Oct; 37(10):947-959. PubMed ID: 38942217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the Effect of Tafamidis on Cardiovascular-Related Hospitalization in NYHA Class III Patients with Transthyretin Amyloid Cardiomyopathy in the Presence of Death.
    Li H; Rozenbaum M; Casey M; Sultan MB
    Cardiology; 2022; 147(4):398-405. PubMed ID: 35853436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms.
    Elliott P; Gundapaneni B; Sultan MB; Ines M; Garcia-Pavia P
    Eur J Heart Fail; 2023 Nov; 25(11):2060-2064. PubMed ID: 37434378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
    Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J
    Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study.
    Garcia-Pavia P; Sultan MB; Gundapaneni B; Sekijima Y; Perfetto F; Hanna M; Witteles R
    JACC Heart Fail; 2024 Jan; 12(1):150-160. PubMed ID: 37943223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy.
    Rettl R; Mann C; Duca F; Dachs TM; Binder C; Ligios LC; Schrutka L; Dalos D; Koschutnik M; Donà C; Kammerlander A; Beitzke D; Loewe C; Charwat-Resl S; Hengstenberg C; Kastner J; Eslam RB; Bonderman D
    Eur Heart J Cardiovasc Imaging; 2022 Jun; 23(6):767-780. PubMed ID: 34788394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of tafamidis on myocardial function and CMR tissue characteristics in transthyretin amyloid cardiomyopathy.
    Dobner S; Bernhard B; Ninck L; Wieser M; Bakula A; Wahl A; Köchli V; Spano G; Boscolo Berto M; Elchinova E; Safarkhanlo Y; Stortecky S; Schütze J; Shiri I; Hunziker L; Gräni C
    ESC Heart Fail; 2024 Oct; 11(5):2759-2768. PubMed ID: 38736040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study.
    Tsai CH; Chao CC; Hsieh ST; Yu AL; Wu YA; Cheng MF; Lee MJ; Chou CH; Shun CT; Hsueh HW; Jyh-Ming Juang J; Tseng PH; Su MY; Lin YH
    Orphanet J Rare Dis; 2023 Sep; 18(1):289. PubMed ID: 37705003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy.
    Rozenbaum MH; Tran D; Bhambri R; Nativi-Nicolau J
    Am J Cardiovasc Drugs; 2022 Jul; 22(4):445-450. PubMed ID: 35353352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.